TheEdgeResearch
Home / Stocks / BNIGF

Beroni Group Limited (BNIGF)

OTC Healthcare Biotechnology
$0.01 ▲ +0.00%
Market Cap
$212,760
Sector
Healthcare
Industry
Biotechnology
Beta
-1.76
52-Wk Range
0.0021-0.0064
CEO
Boqing Zhang
Country
AU
Currency
USD

Beroni Group Limited operates in the Biotechnology industry of the Healthcare sector, headquartered in Sydney, NSW, AU. The stock last traded at $0.01, up 0.00% on the session, giving a market capitalisation of $212,760. On trailing twelve-month figures it carries a trailing P/E of -0.06, a net margin of -661.7%. Its beta of -1.76 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-0.06
Price / Sales
0.47
Price / Book
0.06
EV / EBITDA
-0.38
Gross margin
75.2%
Operating margin
-1898.0%
Net margin
-661.7%
Return on equity
Debt / equity
0.36
Current ratio
1.25
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
5
IPO date
2019-08-27
Headquarters
Sydney, NSW, AU
About Beroni Group Limited

Beroni Group is an international biopharmaceutical enterprise dedicated to the innovation and commercialization of drugs and therapies to combat various global diseases such as cancer and infectious diseases. Its diversified portfolio is comprised of FDA/CE approved virus diagnostic kits, an e-commerce platform for the sale of pharmaceutical products, and a development pipeline targeting oncology and cell therapies. The company has operations in Australia, the United States, China, and Japan.

Comparable companies

Beroni Group Limited is most often compared with the following Healthcare names:

CIRXCSLIDLOCDSUSELGLMJWLRGDEFSEAOFSPGXSSET
More research on BNIGF
BNIGF technical analysis BNIGF TheEdge Score Compare against peers
Open full interactive analysis & DCF →